Cargando…
Immunotherapy Strategies for the Prevention and Treatment of Distinct Stages of Type 1 Diabetes: An Overview
Type 1 diabetes mellitus is a heterogeneous disorder characterized by destruction of pancreatic β cells, culminating in absolute insulin deficiency. The goals of Type 1 diabetes care, established by the Diabetes Control and Complications Trial (DCCT), are to achieve good glycemic control, to prevent...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139632/ https://www.ncbi.nlm.nih.gov/pubmed/32204344 http://dx.doi.org/10.3390/ijms21062103 |
_version_ | 1783518810667483136 |
---|---|
author | Rapini, Novella Schiaffini, Riccardo Fierabracci, Alessandra |
author_facet | Rapini, Novella Schiaffini, Riccardo Fierabracci, Alessandra |
author_sort | Rapini, Novella |
collection | PubMed |
description | Type 1 diabetes mellitus is a heterogeneous disorder characterized by destruction of pancreatic β cells, culminating in absolute insulin deficiency. The goals of Type 1 diabetes care, established by the Diabetes Control and Complications Trial (DCCT), are to achieve good glycemic control, to prevent hyperglycaemia (which is associated with long-term microvascular and macrovascular complications) and to avoid recurrent episodes of hypoglycaemia (which may have adverse effects on cognitive function). However, despite continuing optimization of insulin therapy regimes, the actual hormonal substitutive administration acts only to treat the symptoms without an effect on disease pathology and etiopathogenesis. In recent decades, a great deal of interest has been focused on prevention approaches in high-risk individuals, based on the hypothesis that a therapeutic intervention, if applied at the early stage of disease, might contribute to maintaining endogenous β cell function by preserving the residual β cell reservoir from autoimmune attack. This manuscript provides an overview of the most important immunotherapeutic interventions established so far for Type 1 diabetes treatment at different stages of disease that have reached an advanced stage of assessment. |
format | Online Article Text |
id | pubmed-7139632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71396322020-04-10 Immunotherapy Strategies for the Prevention and Treatment of Distinct Stages of Type 1 Diabetes: An Overview Rapini, Novella Schiaffini, Riccardo Fierabracci, Alessandra Int J Mol Sci Review Type 1 diabetes mellitus is a heterogeneous disorder characterized by destruction of pancreatic β cells, culminating in absolute insulin deficiency. The goals of Type 1 diabetes care, established by the Diabetes Control and Complications Trial (DCCT), are to achieve good glycemic control, to prevent hyperglycaemia (which is associated with long-term microvascular and macrovascular complications) and to avoid recurrent episodes of hypoglycaemia (which may have adverse effects on cognitive function). However, despite continuing optimization of insulin therapy regimes, the actual hormonal substitutive administration acts only to treat the symptoms without an effect on disease pathology and etiopathogenesis. In recent decades, a great deal of interest has been focused on prevention approaches in high-risk individuals, based on the hypothesis that a therapeutic intervention, if applied at the early stage of disease, might contribute to maintaining endogenous β cell function by preserving the residual β cell reservoir from autoimmune attack. This manuscript provides an overview of the most important immunotherapeutic interventions established so far for Type 1 diabetes treatment at different stages of disease that have reached an advanced stage of assessment. MDPI 2020-03-19 /pmc/articles/PMC7139632/ /pubmed/32204344 http://dx.doi.org/10.3390/ijms21062103 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Rapini, Novella Schiaffini, Riccardo Fierabracci, Alessandra Immunotherapy Strategies for the Prevention and Treatment of Distinct Stages of Type 1 Diabetes: An Overview |
title | Immunotherapy Strategies for the Prevention and Treatment of Distinct Stages of Type 1 Diabetes: An Overview |
title_full | Immunotherapy Strategies for the Prevention and Treatment of Distinct Stages of Type 1 Diabetes: An Overview |
title_fullStr | Immunotherapy Strategies for the Prevention and Treatment of Distinct Stages of Type 1 Diabetes: An Overview |
title_full_unstemmed | Immunotherapy Strategies for the Prevention and Treatment of Distinct Stages of Type 1 Diabetes: An Overview |
title_short | Immunotherapy Strategies for the Prevention and Treatment of Distinct Stages of Type 1 Diabetes: An Overview |
title_sort | immunotherapy strategies for the prevention and treatment of distinct stages of type 1 diabetes: an overview |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139632/ https://www.ncbi.nlm.nih.gov/pubmed/32204344 http://dx.doi.org/10.3390/ijms21062103 |
work_keys_str_mv | AT rapininovella immunotherapystrategiesforthepreventionandtreatmentofdistinctstagesoftype1diabetesanoverview AT schiaffiniriccardo immunotherapystrategiesforthepreventionandtreatmentofdistinctstagesoftype1diabetesanoverview AT fierabraccialessandra immunotherapystrategiesforthepreventionandtreatmentofdistinctstagesoftype1diabetesanoverview |